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Bisphenol A [BPA; 2,2-bis(4-hydroxyphenyl)
propane] is a high-production volume chemi-
cal used primarily in manufacturing polycar-
bonate plastic and epoxy resins that can be 
used in impact-resistant safety equipment, 
baby bottles, as protective coatings inside 
metal food containers, and as composites 
and sealants in dentistry (Chapin et al. 2008; 
European Union 2003, 2008; Health Canada 
2008; National Toxicology Program 2008).
In experimental animals, exposure to BPA 
at high doses is associated with estrogen-like 
effects. At doses below the putative lowest 
observed adverse effect level, exposure to BPA 
has resulted in increased prostate gland volume, 
altered development and tissue organization of 
the mammary gland, changes in mammary and 
prostate gland development that may predis-
pose to neoplasia, disruption of sexual differ-
entiation in the brain, and accelerated puberty 
in females (Ceccarelli et al. 2007; Della Seta 
et al. 2006; Durando et al. 2007; Gioiosa 
et al. 2007; Ho et al. 2006; Howdeshell et al. 
1999; Laviola et al. 2005; Murray et al. 2007; 
Negishi et al. 2004; Palanza et al. 2002; Ryan 
and Vandenbergh 2006; Timms et al. 2005). 
The interpretation of the evidence related to 
the low-dose effects of BPA is a subject of 
scientific debate (Chapin et al. 2008; European 
Union 2003; Goodman et al. 2008; Gray et al. 
2004; National Toxicology Program 2008; 
vom Saal and Hughes 2005).
Widespread exposure to BPA among 
the general population (Calafat et al. 2008c; 
Center for the Evaluation of Risks to Human 
Reproduction 2007; National Toxicology 
Program 2008; Vandenberg et al. 2007) likely 
results from ingesting food containing BPA 
(Kang et al. 2006; Vandenberg et al. 2007). 
Acute exposure to BPA may occur in occupa-
tional settings and during treatment with den-
tal materials containing BPA (Chapin et al. 
2008; European Union 2003; Vandenberg 
et al. 2007). BPA may also be used in the ther-
mal paper and polyvinyl chloride (PVC) indus-
tries (European Union 2003, 2008; National 
Toxicology Program 2008). In turn, PVC 
is used in manufacturing medical products, 
including those found in neonatal intensive 
care units (NICUs), such as bags containing 
intravenous fluids and total parenteral nutri-
tion and tubing associated with their adminis-
tration; nasogastric and enteral feeding tubes; 
respiratory masks and endotracheal tubes; and 
umbilical catheters. Di(2-ethylhexyl) phtha-
late (DEHP) is a plasticizer added to PVC in 
a variety of these medical products (Food and 
Drug Administration 2001). Four additional 
phenols, namely benzo  phenone-3 (BP-3), 
methyl paraben (MePB), propyl paraben 
(PrPB), and triclosan (TCS), may also have 
potential applications in health- and in per-
sonal care scenarios. TCS is a broad-spectrum 
antimicrobicide used extensively in medical 
settings (Jones et al. 2000; Weber and Rutala 
2006). BP-3 is used as a sunscreen agent in 
numerous cosmetics and everyday products 
(Gonzalez et al. 2006). MePB and PrPB are 
antimicrobial preservatives used in personal 
care products and pharmaceuticals (Cashman 
and Warshaw 2005). TCS, BP-3, MePB and 
PrPB may be endocrine disruptors (Darbre 
and Harvey 2008; Schlumpf et al. 2001; U.S. 
Environmental Protection Agency 2008), 
and human exposure to these compounds is 
widespread in the United States (Calafat et al. 
2008a, 2008b; Ye et al. 2006a). However, the 
potential health effects of these compounds in 
humans are largely unknown.
Except for DEHP and other phthalates, 
limited data exist on the potential exposure to 
environmental chemicals, including BPA and 
the other four phenols, in premature infants 
undergoing intensive medical treatments. 
Early-life exposures are of great concern with 
regard to the potential for adverse health conse-
quences throughout the life span. Because pre-
mature infants in intensive care units are both 
developmentally and physiologically imma-
ture, they are a potential high-risk population 
following exposure to environmental chem-
icals. We demonstrated previously that the 
intensity of use of products containing DEHP 
in 54 NICU premature infants is associated 
with exposure to DEHP, as reflected in urinary 
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Ob j e c t i v e: We previously demonstrated that exposure to polyvinyl chloride plastic medical devices 
containing di(2-ethylhexyl) phthalate (DEHP) was associated with higher urinary concentrations of 
several DEHP metabolites in 54 premature infants in two neonatal intensive care units than in the 
general population. For 42 of these infants, we evaluated urinary concentrations of several phenols, 
including bisphenol A (BPA), in association with the use of the same medical devices.
MeasureMents: We measured the urinary concentrations of free and total (free plus conjugated) 
species of BPA, triclosan, benzophenone-3, methyl paraben, and propyl paraben.
re s u l t s: The percentage of BPA present as its conjugated species was > 90% in more than three-
quarters of the premature infants. Intensity of use of products containing DEHP was strongly asso-
ciated with BPA total concentrations but not with any other phenol. Adjusting for institution and 
sex, BPA total concentrations among infants in the group of high use of DEHP-containing products 
were 8.75 times as high as among infants in the low use group (p < 0.0001). Similarly, after adjust-
ing for sex and DEHP-containing product use category, BPA total concentrations among infants in 
Institution A were 16.6 times as high as those among infants in Institution B (p < 0.0001).
cO n c l u s i O n: BPA geometric mean urinary concentration (30.3 µg/L) among premature infants 
undergoing intensive therapeutic medical interventions was one order of magnitude higher than 
that among the general population. Conjugated species were the primary urinary metabolites of 
BPA, suggesting that premature infants have some capacity to metabolize BPA. The differences in 
exposure to BPA by intensity of use of DEHP-containing medical products highlight the need for 
further studies to determine the specific source(s) of exposure to BPA.
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concentrations of DEHP metabolites that were 
substantially higher than those among the 
general population (Green et al. 2005; Weuve 
et al. 2006). In this follow-up report, we stud-
ied these premature infants’ intensity of expo-
sure to DEHP-containing medical devices in 
relation to urinary concentrations of several 
environmental phenols, including BPA.
Methods
Study population. In 2003, we studied a 
convenience sample of 54 low-birth-weight 
infants from level III NICUs (which provide 
all newborn care, including mechanical and 
high-frequency ventilation, surgery, and car-
diac catheterization) at two major Boston-area 
(Massachusetts) hospitals (institutions A and 
B), as previously described in detail (Green et al. 
2005). We chose these infants to reflect a range 
of diagnoses (including congenital anomalies 
and developmental and metabolic abnormali-
ties) and NICU care requirements (e.g., ven-
tilation, enteral feedings, parenteral nutrition, 
indwelling catheterization). The eligibility cri-
teria included a) being a patient in the NICU 
at least 3 consecutive days before enrollment; 
b) having a corrected gestational age (gesta-
tional age at birth plus age after birth) of ≤ 44 
weeks; and c) having been born at or transferred 
to either hospital between 1 March and 30 
April 2003. We excluded infants with hyper-
bilirubinemia (> 20 µg/dL), which indicates 
impaired hepatic enzyme function or structural 
integrity (e.g., biliary atresia). We determined 
by observation (we had no access to medical 
records) length of stay in the NICU, primary 
diagnosis, exposure to medical products, ges-
tational age, sex, and whether the infant was 
breast- or formula-fed. We also collected at least 
one urine sample per infant as normally dis-
carded human waste; a protocol-derived record 
number linked each urine sample to an infant. 
We had no access to any personal identifiable 
information, and therefore did not conduct 
parental interviews or seek parental consent. 
The original study protocol was approved 
by the Institutional Review Boards (IRB) of 
Harvard School of Public Health, Brigham and 
Women’s Hospital, and Massachusetts General 
Hospital. In 2008, a protocol for the use of 
the urine samples and data collected using the 
original protocol for assessing exposure to BPA 
and other phenols was deemed exempt from 
IRB review at Harvard School of Public Health 
according to 45 Code of Federal Regulations 
46.102(d) and/or (f) (Department of Health 
and Human Services 2005).
Intensity of use of products containing 
DEHP. Before data collection in 2003, we 
defined three levels of intensity of use of prod-
ucts containing DEHP (low, medium, and 
high) based on a review of medical products 
typically used in both NICUs and manufac-
turer-provided information on the products’ 
DEHP content. The low-DEHP category 
included infants receiving primarily bottle and/
or gavage feedings. The medium-DEHP group 
included infants receiving enteral feedings by 
indwelling gavage tubes either continuously or 
by bolus feedings; intravenous hyperalimenta-
tion by indwelling percutaneous intravenous 
central catheter line or broviac or umbilical 
vessel catheter; and/or continuous positive air-
way pressure by nasal prongs. The high-DEHP 
category included infants receiving continu-
ous indwelling umbilical vein catheterization, 
endotracheal intubation, intravenous hyper-
alimentation, and having an indwelling gavage 
tube (for gastric decompression). As previously 
described in detail (Green et al. 2005), one 
of the study investigators observed the care 
of each infant and, during this observation 
period, inventoried the products used to care 
for each infant. Given this inventory, a priori 
we grouped infants into the categories of low-, 
medium-, and high-use of DEHP-containing 
products. Product use groups did not change 
for any of the infants over the course of obser-
vation. As reported previously, the intensity of 
DEHP-containing product use was strongly 
related to the urinary concentrations of DEHP 
metabolites (Green et al. 2005; Weuve et al. 
2006). For example, among the infants 
included in the present study, median urinary 
concentrations of mono(2-ethylhexyl) phtha-
late, one of the DEHP metabolites, were 6.5, 
27, and 92 µg/L, respectively, for those in the 
low-, medium- and high-DEHP-containing 
product use groups.
Urine collection and analysis. As described 
before (Green et al. 2005), in 2003, spot 
urine samples were collected at the end of 
each infant’s observation period from a cot-
ton gauze placed in the infant’s diaper or from 
the cotton filling of the diaper (we assumed a 
100% recovery of free and conjugated urinary 
species from the diaper or cotton gauze for all 
compounds examined). In 2003, these urine 
samples were analyzed for phthalate metabo-
lites at the Centers for Disease Control and 
Prevention (Atlanta, GA) and the remaining 
samples were stored under controlled condi-
tions at –40°C. In 2008, for this secondary 
analysis, we measured BPA concentrations in 
57 urine archived samples collected from 41 
infants, for some of whom we had up to four 
samples. Of the 16 replicates, four were col-
lected concurrently with the first samples (i.e., 
the diaper/cotton gauze yielded enough urine 
for more than one vial), and the remaining 
samples were collected between 6 and 48 hr 
after the first samples. In addition, we meas-
ured BP-3, PrPB, and TCS in 59 samples 
(from 42 infants), and MePB in 58 samples 
(from 41 infants). At subfreezing storage 
temperatures, the conjugated species of the 
phenols examined are known to be stable for 
6 months (Ye et al. 2007), and unpublished 
data from our laboratory extends this stability 
to at least 30 months. Under the controlled 
sample storage conditions of this study, we 
assumed that both free and total (free plus con-
jugated) species remained stable. Nonetheless, 
the estimated urinary concentrations of the 
free species must be interpreted with caution 
because at the time of the collection of the 
specimens, we did not pre-screen the sampling 
materials for the presence of these phenols.
We measured the free and total urinary 
concentrations of BPA, TCS, BP-3, MePB, 
and PrPB using online solid-phase extraction 
coupled to high-performance liquid chro-
matography (HPLC)–isotope dilution tan-
dem mass spectrometry with peak focusing 
as described before (Ye et al. 2005, 2006b). 
Briefly, the conjugated species of the phe-
nols in 100 µL of urine were hydrolyzed with 
β-glucuronidase/sulfatase (Helix pomatia); 
this deconjugation step was omitted when 
measuring the concentrations of the free spe-
cies. After hydrolysis, samples were acidified 
with 0.1 M formic acid; the phenols were 
preconcentrated by online solid phase extrac-
tion, separated by reversed-phase HPLC, and 
detected by atmospheric pressure chemical 
ionization–tandem mass spectrometry. The 
limits of detection (LODs)—calculated as 
3S0, where S0 is the standard deviation as 
the concentration approaches zero (Taylor 
1987)—were 0.2 µg/L (PrPB), 0.4 µg/L 
(BPA, BP-3), 1.0 µg/L (MePB), and 2.3 µg/L 
(TCS). We analyzed low-concentration (~4 
to ~25 µg/L) and high-concentration (~10 to 
~65 µg/L) quality-control materials, prepared 
with pooled human urine spiked with the 
analytes of interest, with standard, reagent 
blank, and infants’ samples. Samples with 
concentrations of the analytes above the high-
est calibration standard were re-extracted 
using less urine, and the concentrations were 
calculated after adjusting for the dilution.
Assessment of other variables. Because 
the urine sample collection was anonymous 
and not based on review of medical records, 
information on gestational age, length of stay 
in the NICU, and whether the infant was 
breast- or formula-fed was not available or 
was incomplete for many infants. We used 
the intensity of use of products containing 
DEHP, which correlates with the degree of 
medical support required, as a blunt surro-
gate measure for illness severity (Weuve et al. 
2006). Nonetheless, because of the anony-
mous design of the study, we were unable 
to distinguish levels of illness severity within 
product-use group. We were able to observe 
breast- and formula-feeding status of 24 of 
the infants. Eleven infants were breast-fed 
(or fed breast milk), of whom 3 were also 
receiving formula. In contrast, 16 infants were 
formula-fed (including the 3 who were also 
breast-fed). We had BPA measurements for Exposure to BPA in NICU premature infants
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14 of the formula-fed infants, but only for 4 
of the breast-fed infants.
Statistical analysis. Unless noted, we per-
formed the statistical analyses using the total 
concentrations of the phenols. For each phe-
nol, urinary concentrations below the LOD 
were assigned a value of LOD divided by the 
square root of 2 (Hornung and Reed 1990). 
We computed Spearman correlations between 
the free and total concentrations of BPA and, 
to evaluate the variability of urinary concen-
trations in specimens collected from the same 
infant, between replicate measures. In addi-
tion, to explore the co-occurrence of expo-
sures to phenols and phthalates in the NICU 
environment, we computed Spearman cor-
relations among urinary concentrations of the 
phenols and the five phthalate metabolites we 
evaluated in our previous work (Green et al. 
2005; Weuve et al. 2006). For these analy-
ses we computed both crude and institution-
  adjusted correlations, because institution 
confounded the associations between BPA 
and the DEHP metabolites. For the crude 
comparisons of urinary concentrations of 
each phenol by sex, institution, or DEHP-
containing product-use group, we used the 
Kruskal–Wallis nonparametric test. We also 
used linear mixed effects regression to com-
pare urinary concentrations of each phenol 
across DEHP-containing product-use groups, 
adjusting for institution and infants’ sex, and 
accounting for the correlations between rep-
licate measures among the same infants. We 
fit separate regression models for each phe-
nol, using the first two concentrations avail-
able for each infant, resulting in 54, 56, 56, 
and 55 urine samples used in the models of 
BPA, BP-3, PrPb, and MePB, respectively. 
We did not fit models for TCS because too 
few urine samples had detectable levels of this 
phenol. To stabilize the variances of the uri-
nary phenol concentrations, we used the log-
transformed concentration as the dependent 
variable in the regression models. Therefore, 
when exponentiated, the estimated regres-
sion parameters in each phenol model are 
interpreted as the urinary concentration for 
a given independent variable expressed as a 
proportion (or multiple) of the urinary con-
centration in that variable’s reference level; for 
example, in the BPA model, the exponenti-
ated regression parameter for the medium-
DEHP product-use group is the estimated 
urinary BPA concentration in this group as a 
proportion of that in the low-DEHP product-
use group. We conducted all analyses with 
SAS software, version 9.1.3 (SAS Institute 
Inc., Cary, NC).
Results
Forty-one premature infants had at least one 
urine sample available for analysis of BPA and 
MePB (42 for TCS, BP-3, and PrPB). We 
detected BPA in all of the first set of urine 
samples collected from these infants at total 
concentrations ranging from 1.6 to 946 µg/L; 
the geometric mean was 30.3 µg/L (Table 1). 
MePB and PrPB were also detected in all of 
the samples and BP-3 in all but two samples 
(Table 1). TCS was detected in approximately 
19% of the samples and therefore was not 
included in any further statistical analysis. Of 
interest, the free species of some of these phe-
nols were detected slightly less frequently and 
at substantially lower concentrations than the 
conjugated species (Table 1). For example, free 
BPA was detected in 92% of the samples; the 
median (1.7 µg/L) and highest concentrations 
(17.3 µg/L) were an order of magnitude lower 
than the total concentrations. Of interest, the 
concentrations of free and conjugated species 
of BPA showed a linear relationship (Spearman 
correlation, r = 0.86) throughout the range of 
total BPA concentrations observed (Figure 1). 
Because of the limited amount of urine avail-
able for analysis, the concentration of free spe-
cies could not be measured in all samples.
The infants in this study were roughly 
equally distributed between the two institu-
tions, and about 38% (information on sex 
was missing for one of the infants) were male 
(Table 2). Fewer infants were exposed to 
DEHP-containing products at low intensity 
of use than at medium or high intensity of use 
(Table 2).
Two or more replicate samples were avail-
able for 14 infants (13 for BPA); we used the 
first two of these samples to assess variability 
in urinary concentrations within individual 
infants (Table 3). The repeated urinary mea-
surements from the same infants were highly 
correlated for BPA and BP-3, and also cor-
related, although to a lesser extent, for MePB 
and PrPB. As expected, the correlations 
between the concurrent (i.e., more than one 
urine sample collected from a single diaper or 
cotton gauze) measurements were excellent 
(all Spearman r ≥ 0.95) (Table 3).
As has been reported (Ye et al. 2006a), we 
found that institution-adjusted urinary con-
centrations of MePB and PrPB were highly 
correlated (Spearman r = 0.73, p < 0.0001), 
suggesting that human exposures to these para-
bens most likely share common pathways. BPA 
was moderately correlated with MePB (r = 0.40, 
p = 0.01). Notably, however, BPA was cor-
related with the phthalate metabolites, includ-
ing the three metabolites of DEHP among 
which it was strongly correlated with DEHP 
oxidative metabolites mono(2-ethyl-5-hydroxy-
hexyl phthalate (r = 0.57, p < 0.0001) and   
mono(2-ethyl-5-oxohexyl) phthalate (r = 0.57, 
p < 0.0002). The remaining institution-adjusted 
correlations among the different phenols with 
each other and with the phthalate metabolites 
measured before (Green et al. 2005; Weuve 
et al. 2006) were weak to moderate (Table 4).
Table 1. Distribution of the urinary concentrations of phenols (µg/L)a in hospitalized premature infants.
    No.     Geometric  Range  NHANES 2003–2004b
Compound  Species  of infants  No. < LOD  mean (SD)  Median  Minimum  Maximum  Median  95th percentile
BP-3  Total  42  2  3.4 (4.8)  2.4   < LOD (0.4)  176  17.2  227
  Free  36  17  NA  NA   < LOD (0.4)  4.1     
BPA  Total  41  0  30.3 (5.2)  28.6  1.6  946  3.7   16.0
  Free  37  3  1.8 (3.2)  1.7   < LOD (0.4)  17.3     
MePB  Total  41  0  203 (4.7)  243  10.1  4,010  43.9c   680c
  Free  34  0  32 (4.9)  23  2.2  515     
PrPB  Total  42  0  16.8 (4.9)  17.0  1.3  1,360  9.1c  279c
  Free  37  0  2.6 (5.2)  1.7  0.3  171     
TCS  Total  42  34  NA  NA   < LOD (2.3)  16.7  5.9  148
  Free  37  36  NA  NA   < LOD (2.3)  3.4     
aThe total concentrations are the sum of the free plus conjugated species of each phenol. We calculated geometric means and medians if the frequency of detection was > 60%. The 
estimated concentrations of free species must be interpreted with caution because at the time of the collection of the urine specimens, we did not prescreen the sampling materials 
for the presence of these phenols. bData from 314 children 6–11 years of age from NHANES (National Health and Nutrition Examination Survey) 2003–2004 for BP-3 (Calafat et al. 2008a), 
BPA (Calafat et al. 2008c), and TCS (Calafat et al. 2008b). cData from a group of 100 dults (Ye et al. 206).
Figure 1. Correlation between free and total BPA 
urinary concentrations for 37 premature infants, 
displayed in log-10 scale (r = 0.86).
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Of the 41 infants who had at least one 
BPA measure, gestational age data were avail-
able for only 16 of them. After dividing the 
group roughly along the median gestational age 
(25–27 weeks vs. 28–34 weeks), the median 
total BPA concentrations was higher (Kruskal–
Wallis p-value = 0.06) for the younger 
(242 µg/L) than for the older (29 µg/L) infants 
(based on gestational age). For the 25 infants 
for whom we had information about length of 
stay in the NICU, BPA concentrations did not 
appear to vary across long (14–90 days) versus 
short (2–13 days) length of stay. The difference 
in BPA concentrations for the breast-fed (or 
fed breast milk) infants (n = 4) and the for-
mula fed infants (n = 14) was not statistically 
  significant (p = 0.7).
In the crude analyses, urinary BPA con-
centrations were significantly higher among 
infants at institution A than at institution B 
(p < 0.0001; Table 2). Concentrations of the 
other phenols measured were similar across 
institutions (Table 2). Urinary concentra-
tions of BPA and the other three phenols did 
not vary substantially by infants’ sex, and no 
consistent associations were present between 
intensity of DEHP-containing product use 
and urinary concentrations of any of the phe-
nols examined (Table 2).
On adjusting for infants’ sex and intensity 
of use of products containing DEHP, the 
association between institution and BPA con-
centrations persisted (Table 5). On average, 
urinary concentrations of BPA among infants 
hospitalized at institution A were almost 17 
times greater than concentrations among 
infants at institution B (p < 0.0001). By con-
trast, infants hospitalized at Institution A had 
BP-3 urinary concentrations that were, on 
average, about one-third the concentrations 
among infants at institution B (p = 0.04). 
Concentrations of the two parabens did not 
vary consistently by DEHP-containing prod-
uct use group or institution. In these adjusted 
analyses, none of the phenol concentrations 
varied by infants’ sex.
 The institution- and sex-adjusted asso-
ciations between the use of medical prod-
ucts containing DEHP group and urinary 
concentrations were highly significant for BPA 
but not for any of the other phenols (Table 5). 
Compared with infants exposed at low inten-
sity to DEHP-containing products, infants 
exposed at medium intensity had BPA con-
centrations that were 3.42 times as high [95% 
confidence interval (CI), 1.45–8.09], and 
infants exposed at high intensity had concen-
trations that were 8.75 times as high (95% CI, 
3.36–22.8). The results of this sex- and institu-
tion-adjusted analysis differed from the crude 
analyses, shown in Table 2, which did not 
show marked differences in BPA concentra-
tion by DEHP group. Similarly, results from 
linear mixed effects regression models of BPA 
that did not adjust for sex or institution also 
showed no significant differences in BPA con-
centration by DEHP-containing product use 
group (data not shown). These different find-
ings were most likely attributable to negative 
confounding by institution; infants at institu-
tion B had lower BPA concentrations but were 
much more likely than infants at institution A 
to be exposed at high intensity (29% vs. 7%) 
to DEHP-containing products.
Discussion
We frequently detected BPA and three other 
phenols (BP-3, MePB, and PrPB) in this group 
of premature infants. The median urinary con-
centrations of BP-3 in these infants were about 
one order of magnitude lower than the concen-
trations reported by the National Health and 
Nutrition Examination Survey (NHANES) 
2003–2004 for children 6–11 years of age 
in the U.S. general population (Calafat et al. 
2008a). Similarly, the low frequency of detec-
tion of TCS among these infants suggests that, 
although TCS may be in products used by 
workers in health care settings, infants’ expo-
sure to TCS in NICUs does not appear to be 
higher than that of the general population. We 
found that the median urinary concentrations 
of MePB and PrPB in the infants examined 
were higher than the median observed among 
a group of 100 adults in the United States (Ye 
et al. 2006a), but lower than the 95th percentile 
concentrations in the same group of adults; 
no data exist on the extent of paraben expo-
sure among children. These results suggest that 
the use of products that contain parabens in 
Table 2. Median and 25th and 75th percentile concentrations of urinary phenols (µg/L) in hospitalized premature infants, by intensity of use of products containing 
DEHP, institution, and sex.
  BP-3  BPA  MePB  PrPB
  No.  25th  Median  75th  p-Valuea  No.  25th  Median  75th  p-Valuea  No.  25th  Median  75th  p-Valuea  No.  25th  Median  75th  p-Valuea
DEHP-containing product use
  High  15  1.2  2.6  7.6  0.5  14  10.4  24.0  54.6  0.9  15  158  340  1,450  0.07  15  11.7  21.3  44.5  0.3
  Medium  17  1.1  1.3  4.4    17  4.8  46.7  88.7    17  43  114  325    17  3.4  8.9  19.1 
  Low  10  1.6  4.1  7.6    10  11.5  29.6  35.6    9  69  177  1,560    10  2.9  24.9  142 
Sex 
  Male  16  1.0  3.3  10.8    16  9.1  26.9  210.9    16  103  333  553    16  6.3  15.1  53.9 
  Female  25  1.2  1.9  3.6  0.7  24  8.3  27.1  54.8  0.6  24  52  182  534  0.3  25  5.3  18.3  44.3  1
Institution
  A  20  1.0  1.8  5.4  0.2  20  29.6  69.9  391  < 0.0001  19  32  317  598  0.8  20  2.8  7.1  40.0  0.1
  B  22  1.2  2.9  12.8    21  4.9  9.5  28.6    22  63  191  496    22  12.0  18.7  61.2 
aKruskal–Wallis nonparametric test for differences by group.
Table 3. Spearman correlations between repeated urinary concentrations among premature infants (first 
two specimens).
 N o. of infants with   Spearman    No. of concurrent  Spearman
  ≥ 2 measurements  correlation  p-Value  measurements  correlation  p-Value
BP-3  14  0.86   < 0.0001  4  0.95  0.05
BPA  13  0.97   < 0.0001  4  1.00   < 0.0001
MePB  14  0.62  0.02  4  1.00   < 0.0001
PrPB  14  0.47  0.09  4  1.00   < 0.0001
Table 4. Institution-adjusted Spearman correlations between the total urinary concentrations of different 
analytes among premature infants (all n = 41 or 42).
  BPA  MePB  PrPB  MEHPa  MEHHPa  MEOHPa  MBPa  MBzPa
BP-3  –0.04  0.16  0.02  –0.10  –0.08  –0.06  0.11  0.06
p-Value  0.8  0.3  0.9   0.6  0.6  0.7   0.5  0.7
BPA    0.40  0.21  0.29  0.57  0.57  0.31  0.32
p-Value    0.01  0.2  0.08  0.0001  0.0002  0.06  0.05
MePB      0.73  0.29  0.34  0.43  0.28  0.12
p-Value       < .0001  0.08  0.03  0.01  0.09  0.5
PrPB        0.17  –0.01  0.07  –0.06  –0.08
p-Value        0.3  0.9  0.7  0.7  0.6
Abbreviations: MBP, monobutyl phthalate; MBzP, monobenzyl phthalate; MEHHP, mono(2-ethyl-5-hydroxyhexyl) phtha-
late; MEHP, mono(2-ethylhexyl) phthalate; MEOHP, mono(2-ethyl-5-oxohexyl) phthalate.
aData from Green et al. (2005); Weuve et al. (2006). Exposure to BPA in NICU premature infants
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the treatment of NICU premature infants can 
result in exposure levels that may be higher than 
those observed among the general population.
By contrast, we found that the median uri-
nary concentrations of BPA among the infants 
(28.6 µg/L) were about one order of magni-
tude higher than the median concentration 
(3.7 µg/L) and almost twice the 95th percentile 
concentration (16.0 µg/L) among children 6–11 
years of age who were examined as part of the 
NHANES 2003–2004 (Calafat et al. 2008c). 
These data suggest that exposure to BPA among 
the infants in our study was much higher than 
among any of the populations examined in the 
United States (Chapin et al. 2008; National 
Toxicology Program 2008). Furthermore, that 
> 90% of the BPA excreted in the urine was in 
its conjugated (e.g., glucuronide, sulfate) form 
excludes the possibility that the BPA concentra-
tions measured in these infants’ urine resulted 
primarily from contamination and supports 
the validity of our analytical data. More impor-
tant, our findings suggest that even premature 
infants have some capacity to conjugate BPA, 
in agreement with previous studies suggesting 
that critically ill premature infants could, to a 
certain extent, metabolize DEHP metabolites to 
their urinary glucuronides (Calafat et al. 2004). 
Furthermore, the fact that the association 
between the concentrations of free and total 
BPA was linear across the range of observed 
total BPA concentrations suggests that satura-
tion of the enzyme(s) responsible for the conju-
gation of BPA did not occur even at total BPA 
concentrations orders of magnitude higher those 
reported among the general U.S. population. 
Nevertheless, although shortly after birth some 
hepatic enzymes involved in phase II metabo-
lism (such as UDP-glucuronosyltransferases) 
can be activated even in premature infants 
(Blake et al. 2005; Burchell et al. 1989; 
Jansen et al. 1992; Leakey et al. 1987), these 
glucuronidation pathways are not expected to 
be functional at adult rates until months after 
birth (de Wildt et al. 1999). Studies designed 
to confirm these preliminary findings are war-
ranted to examine the percentage of free BPA 
and conjugation ability of infants and young 
children, including premature infants.
In the crude analyses, the median total BPA 
concentrations were about one order of mag-
nitude higher among the infants 25–27 weeks 
of age than among the older (28–34 weeks) 
infants. Of interest, among the younger infants 
(gestational age, 25–27 weeks), five were in the 
medium-intensity and three were in the high-
intensity group exposed to DEHP-containing 
products. By contrast, five of the older infants 
(gestational age, 28–34 weeks) were in the 
low-intensity and three were in the medium-
intensity group. Therefore, the observed dif-
ferences in BPA concentrations by gestational 
age are likely to be attributable partially to the 
treatment given to the infants. On the other 
hand, the length of stay in the NICU or feeding 
method (formula vs. breast milk) did not result 
in significant differences in BPA concentrations. 
However, because information on gestational 
age, length of stay in the NICU, and feeding 
type was incomplete for many infants, these 
results are preliminary; the potential association 
of these variables with BPA exposure should be 
addressed in future research. 
In this follow-up study of premature infants 
receiving care in two NICUs, we found mod-
erate to strong institution-adjusted correla-
tions between urinary concentrations of BPA 
and the metabolites of DEHP, indicating that 
BPA and DEHP may share common exposure 
sources. Consistent with this possibility, we 
found strong associations between the use of 
DEHP-containing medical devices and uri-
nary concentrations of BPA. Specifically, after 
adjustment for infants’ sex and institution, 
urinary BPA concentrations among infants 
who were exposed at high intensity to DEHP-
containing products were almost nine times 
as high as those in the low-intensity group. 
Urinary BPA concentrations among infants 
who were exposed at medium intensity to 
DEHP-containing products were more than 
three times as high as those in the low-intensity 
group. Furthermore, urinary BPA concentra-
tions were higher among infants hospitalized at 
institution A than among infants hospitalized at 
institution B, regardless of DEHP product-use 
group. Of interest, the urinary concentrations 
of DEHP metabolites in infants of institution 
B were higher than in infants of institution A 
and might have reflected the extensive use of 
two DEHP-containing PVC medical devices at 
institution B that were used sparingly in institu-
tion A (Green et al. 2005; Weuve et al. 2006). 
We have no information about the presence of 
BPA in any of the medical or other products 
used in the care of the infants. Therefore, we 
cannot rule out that the two institutions used 
products for the care of the infants that also 
differed in their BPA content which may have 
contributed to the observed differences.
Moreover, BPA may leach from other 
baby and consumer products, including those 
made from polycarbonate plastic and epoxy 
resins (European Union 2008; Health Canada 
2008; National Toxicology Program 2008); 
unfortunately, we did not collect information 
related to the use of these products. Taken 
together, these findings suggest that expo-
sure to BPA in NICUs may result from the 
use of specific medical products; these prod-
ucts may also be sources of exposure to other 
compounds, such as DEHP. However, this 
study’s small size, narrow range of descriptive 
data on the infants and the products used for 
their care (except for those related to DEHP 
content), and lack of environmental measures 
from the infants’ NICU surroundings limited 
our ability to conduct more detailed analyses.
Although the data suggest the presence of 
BPA in medical devices/products, we can not 
determine with certainty the source(s) of BPA 
because we did not test for BPA in the medi-
cal devices and products used or the dietary 
liquids ingested (e.g., breast milk or formula). 
Therefore, we cannot rule out that the milk or 
formula the infants consumed was the source 
of BPA exposure, as BPA has been detected 
both in human milk and formula (National 
Toxicology Program 2008). However, we have 
no reason to suspect that the amounts of milk 
or formula consumed by the premature infants 
Table 5. Multivariable-adjusteda relative urinary concentrations of the phenolsb (95% CI) in hospitalized premature infants, by use of DEHP-containing products, 
infant’s sex, and institution.
  BP-3 (n = 56)  BPA (n = 54)  MePB (n = 55)  PrPB (n = 56)
  Concentration (95% CI)  p-Value  Concentration (95% CI)  p-Value  Concentration (95% CI)  p-Value  Concentration (95% CI)  p-Value
DEHP-containing product use
  High  0.36 (0.08–1.53)    8.75 (3.36–22.8)    2.48 (0.76–8.05)    1.09 (0.30–3.93) 
  Medium  0.52 (0.14–1.93)  0.36c  3.42 (1.45–8.09)  0.0003c  0.65 (0.21–1.99)  0.01c  0.59 (0.18–1.96)  0.4c
  Low  1 (Referent)    1 (Referent)    1 (Referent)    1 (Referent) 
Sex 
  Male  1.61 (0.57–4.49)  0.4c  1.07 (0.55–2.08)  0.9c  1.53 (0.68–3.46)  0.3c  0.96 (0.39–2.36)  0.9c
  Female  1 (Referent)    1 (Referent)    1 (Referent)    1 (Referent) 
Institution
  A  0.31 (0.10–0.96)  0.04c  16.6 (7.98–34.6)   < 0.0001c  1.29 (0.54–3.08)  0.6c  0.44 (0.17–1.16)  0.1c
  B  1 (Referent)    1 (Referent)    1 (Referent)    1 (Referent) 
aEach metabolite is represented by its own model that is adjusted for DEHP-containing-product use group, sex, and institution. bResults expressed as multiples of the concentrations in 
the reference group. For example, infants in the high use of DEHP-containing products group have BPA concentrations nearly 9 times the concentrations among infants in the low use of 
DEHP-containing product group. cp-Value corresponds to overall association between variable and phenol concentration.Calafat et al.
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differed considerably by the use of medical 
products containing DEHP and the institution 
in which they were patients. 
To our knowledge, this study is the first 
to describe infants’ exposure to BPA, TCS, 
BP-3, MePB, and PrPB. In conjunction with 
the previous data collected on phthalates for 
the same group of premature infants (Green 
et al. 2005; Weuve et al. 2006), our findings 
suggest that infants may be exposed during 
critical periods of their development to several 
potential reproductive and developmental toxi-
cants at levels higher than those reported for 
the general population. However, this was an 
exposure study, and we were therefore unable 
to explore whether such exposures were associ-
ated with adverse health effects in these infants. 
This study is also the first to demonstrate that 
increasing intensity of DEHP-containing 
PVC product use is proportional to exposure 
to BPA, as was reflected in significant eleva-
tions in urinary concentrations of BPA and the 
absence of similar elevations in urinary concen-
trations of the other four additional phenols 
examined. Concerns related to BPA toxicity as 
well as high BPA exposure levels in this sensi-
tive population of low-birth-weight premature 
infants may justify using products that do not 
contain BPA while not compromising the qual-
ity of medical care. Future research is needed to 
establish the source(s) and the potential health 
outcomes of these exposures to BPA.
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